ConductScience.org, home

Trial · NCT02152228

A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism

NCT02152228, Phase 2, Completed, Entera Bio Ltd.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism. Trials, record NCT02152228. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02152228

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism
NCT number
NCT02152228
Status
Completed
Phases
Phase 2
Enrollment
20 participants, actual
Lead sponsor
Entera Bio Ltd.
Conditions
Hypoparathyroidism
Interventions
EnteraBio's Oral Parathyroid Hormone (1-34)
First posted
2014-06-02
Last updated
2015-10-07

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of participants with adverse eventsup to 17 weekssafety will be measured by monitoring and recording adverse events related to hyper- and hypocalcemia
PrimaryReduction in use of exogenous calcium supplement and/or alpha D3 supplementup to 17 weeks
PrimaryTolerability- The rate of discontinuation of patients' participation in the study due to adverse eventsup to 17 weeks
PrimaryPlasma calcium levelsat baseline and 60 minutes post-dose
PrimaryPeak Plasma Concentration (Cmax)of treatmentat baseline and time-points post-doseTo study the pharmacokinetic profile of PTH absorption
SecondaryThe volunteers' compliance to treatmentup to 17 weeksCompliance to treatment defined as proportion taking \>80% study medication (good), 60-80% (satisfactory) and \<60% (poor)
SecondaryPatient quality of lifeup to 17 weeksPatients will report a Quality Of Life (QOL) review

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02152228

GET https://conductscience.org/api/trials/v1/NCT02152228/registered